<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279080</url>
  </required_header>
  <id_info>
    <org_study_id>1201/2018</org_study_id>
    <nct_id>NCT04279080</nct_id>
  </id_info>
  <brief_title>LARS in Ovarian Cancer Patients</brief_title>
  <official_title>Low Anterior Resection Syndrome (LARS) in Ovarian Cancer Patients - a Multi-centre Comparative Analysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Low anterior resection syndrome (LARS) is a common functional disorder after low anterior
      resection impacting quality of life. Data on LARS derives nearly exclusively from rectal
      cancer studies. Therefore, the study was designed to assess LARS in advanced epithelial
      ovarian cancer (EOC) patients, who underwent rectal resection and to compare it with a female
      rectal cancer cohort.

      Methods:

      A cross-sectional multi-centre analysis was performed for female patients suffering from
      either rectal or EOC who received a low anterior resection as part of their therapy regimen.
      None of the patients received pre- or postoperative radiotherapy. LARS was defined by using
      the validated LARS score and its severity was divided into &quot;no&quot;, &quot;minor&quot; and &quot;major LARS&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2003</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>functional bowel outcome after low anterior resection</measure>
    <time_frame>1 year</time_frame>
    <description>low anterior resection syndrome score, questionnaire via telephone call or personal contact</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Low Anterior Resection Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>rectal cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>ovarian cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low anterior resection syndrome evaluation</intervention_name>
    <description>evaluation of postoperative functional bowel outcome</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A cross-sectional multi-centre analysis was performed for female patients suffering from
        either rectal or EOC who received a low anterior resection as part of their therapy
        regimen.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  low anterior resection because of ovarian or rectal cancer

        Exclusion Criteria:

          -  neoadjuvant or adjuvant radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Felix Harpain</investigator_full_name>
    <investigator_title>Principle Investigator, M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

